Generic drug options did not significantly reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs paper published May 10.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
